4D Molecular Therapeutics FDMT 深 沪
等待开盘 11-04 09:30:00 美东时间
11.22
-0.280
-2.43%
华盛通- 最 高11.70
- 今 开11.60
- 成交量 101.92万股
- 最 低 10.60
- 昨 收 11.50
- 总市值 5.24亿
- 52周最高 12.34
- 市盈率 静 --
- 换手率 2.18%
- 52周最低 2.235
- 委 比 99.01%
- 总股本 4670.25万
- 历史最高 55.11
- 量 比 0.95
- 振 幅 9.57%
- 历史最低 2.235
- 每 手 1
- 风险率 2.15%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多4DMT Announces Exclusive License Agreement with Otsuka Pharmaceutical Co., Ltd. for Development and Commercialization of 4D-150 in Asia-Pacific
4DMolecular Therapeutics (4DMT) has entered into a strategic partnership with Otsuka Pharmaceutical Co., Ltd. to develop and commercialize 4D-150 for the treatment of wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME) in the Asia-Pacific region. Under the agreement, 4DMT will receive an upfront cash payment of $85 million and expects at least $50 million in cost sharing over three years. The partnership also includes ...
10-31 03:02
美股大行评级 | 富国银行上调苹果目标价升至290美元；"卖出"！花旗下调NuScale Power、阿特斯太阳能评级
今日重点评级关注：摩根大通：维持Cogent Biosciences"超配"评级，目标价从30美元升至44美元；Piper Sandler：维持Vital Energy"中性"评级，目标价从16美元升至30美元
10-22 10:10
Beyond The Numbers: 4 Analysts Discuss 4D Molecular Therapeutics Stock
4 analysts have shared their evaluations of 4D Molecular Therapeutics (NASDAQ:F...
10-22 05:00
RBC Capital Reiterates Outperform on 4D Molecular Therapeutics, Maintains $26 Price Target
RBC Capital analyst Lisa Walter reiterates 4D Molecular Therapeutics (NASDAQ:FDMT) with a Outperform and maintains $26 price target.
10-21 22:28
4DMT to Participate in Chardan's 9th Annual Genetic Medicines Conference
4DMT will participate in panel discussions at Chardan's 9th Annual Genetic Medicines Conference on October 21, 2025. The panels focus on "In Vivo Gene Therapy: Breaking into Competitive Ophthalmic Indications" (9:30 a.m. ET) and "In Vivo Gene Therapies in the Lung: Treating CF and Beyond" (2:00 p.m. ET). Links to webcasts are provided, and archived copies will be available on the company's website. 4DMT is a biotech company advancing therapies to...
10-14 12:00
4DMT Advances 4D-710 to Phase 2 with Additional Funding and Support from the Cystic Fibrosis Foundation
The Cystic Fibrosis Foundation has committed up to $11 million in additional funding to support the development of 4D-710, a genetic medicine for cystic fibrosis (CF) lung disease, with an initial tranche of $7.5 million. This funding will accelerate the advancement of 4D-710, including a second dosing cohort in Phase 1, Phase 2 enrollment with a pivotal dose of 2.5E14 vg, and preparation for Phase 3. The CF Foundation has now invested nearly $32...
10-13 12:00
2025 Q3生物制药裁员汇总
（来源：药研网） 金秋十月，凉风拂过，却未能带来行业期盼已久的复苏。 国外媒体Fierce Biotech 最新数据显示，刚过去的第三季度，共发生 62 起裁员...
10-09 14:47
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Gainers Bone Biologics (NASDAQ:BBLG) shares increased by 30.4% to $2.7 during ...
09-04 20:08
Jim Cramer: AppLovin Calls For Prudence, This Health Care Stock Is 'Pure Spec'
Jim Cramer doesn't recommend buying more AppLovin stock. "Let's take a little off the table just to be prudent," he said.
09-03 19:46
